Company: MIRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024077
Chunk: 13

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 13
---
 of the Company’s common stock. The Company received $151,023 in net proceeds from this transaction.

12

CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS

This
Report contains “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act) that reflect our current expectations and views of future
events. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”,
or “continue” or the negative of these terms or other similar expressions. In particular, statements about our clinical trials
and expectations regarding such trials, the markets in which we operate, including growth of such markets, and our expectations, beliefs,
plans, strategies, objectives, prospects, assumptions, or future events or performance contained in this Report generally under the heading
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements.

We
have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these
expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed
in this Report under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
may cause our actual results, performance, or achievements to differ materially from any future results, performance or achievements
expressed or implied by these forward-looking statements, or could affect our share price. Important factors that could cause actual
results or events to differ materially from those expressed in forward-looking statements include, but are not limited to, the following:

    ●
    our
    reliance on related parties for potential funding and our license for Ketamir-2;

    ●
    our
    potential transaction with SKNY Pharmaceuticals, Inc.;

    ●
    our
    ability to obtain and maintain regulatory approval of our product candidates;

    ●
    our
    ability to successfully commercialize and market our product candidates, if approved;

    ●
    our
    ability to contract